Advanced Filters
noise

dermatitis-atopic Clinical Trials

A listing of dermatitis-atopic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 183 clinical trials
M Monique PM Andriessen, MD PhD

The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

The goal of this randomized controlled trial is to study the (cost)effectiveness of NB-UVB phototherapy in patients with atopic eczema/atopic dermatitis. Half of the participants will undergo a course of NB-UVB phototherapy of 8-16 weeks and apply optimal topical therapy (OTT) for a minimum of 3 months. Researchers will compare …

18 - 100 years of age Both Phase N/A

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab …

18 - 100 years of age Both Phase 4
C Christa Reikert

Topical ENS-002 for Atopic Dermatitis in Adults

The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.

18 - 100 years of age Both Phase 1

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

18 - 100 years of age Both Phase 2
S SNP Center Inquiry

Seal, Stopping Eczema and Allergy Study

This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use …

1 - 12 years of age Both Phase 2
Q Quinn Thibodeaux, MD

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

18 - 100 years of age Both Phase 4
J Jessica YL Ching, MSc

A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema

Atopic eczema causes significant disease burdens worldwide. Some studies reported gastrointestinal symptoms in eczema patients which could be related to gut microbiota change. A unique gastrointestinal microflora pattern has also been observed in atopic dermatitis patients when compared with healthy controls. To date, no adult formula is specific for alleviating …

18 - 100 years of age Both Phase N/A
M Moshe Bressler, DO

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"

18 - 100 years of age Both Phase 4
W Wioleta MALINOWSKA

Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.

Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities. The aim of this study is to assess the efficacy of a product for atopic skin versus a placebo. Primary objectives …

3 - 12 years of age Both Phase N/A

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

12 - 100 years of age Both Phase 3

Rewrite in simple language using AI